Data Favor Continuous Anti-PD-1 Therapy in NSCLC

(MedPage Today) -- Patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (Opdivo) lived significantly longer when they continued treatment instead of stopping after 1 year, according to the first randomized data on the...